Recent Analysts’ Ratings Changes for Incyte (INCY)

Incyte (NASDAQ: INCY) has recently received a number of price target changes and ratings updates:

• 6/16/2025 – Incyte was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating. They now have a $107.00 price target on the stock, up previously from $75.00.
• 6/3/2025 – Incyte had its “buy” rating reaffirmed by analysts at Citigroup Inc..
• 6/3/2025 – Incyte had its “neutral” rating reaffirmed by analysts at UBS Group AG. They now have a $61.00 price target on the stock.
• 5/27/2025 – Incyte had its price target raised by analysts at Truist Financial Co. from $72.00 to $73.00. They now have a “hold” rating on the stock.
• 4/30/2025 – Incyte was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 4/30/2025 – Incyte had its price target raised by analysts at Royal Bank of Canada from $64.00 to $67.00. They now have a “sector perform” rating on the stock.
• 4/30/2025 – Incyte had its price target raised by analysts at Wells Fargo & Company from $58.00 to $59.00. They now have an “equal weight” rating on the stock.
• 4/21/2025 – Incyte had its price target lowered by analysts at JPMorgan Chase & Co. from $70.00 to $68.00. They now have a “neutral” rating on the stock.

Incyte Stock Down 2.5%

Shares of NASDAQ INCY traded down $1.77 during mid-day trading on Tuesday, hitting $69.45. The company had a trading volume of 731,066 shares, compared to its average volume of 2,074,353. Incyte Co. has a one year low of $53.56 and a one year high of $83.95. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $13.44 billion, a PE ratio of 257.23, a price-to-earnings-growth ratio of 0.41 and a beta of 0.67. The firm has a 50-day simple moving average of $62.59 and a two-hundred day simple moving average of $66.95.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $1.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.15. Incyte had a return on equity of 0.05% and a net margin of 0.77%. The company had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $996.17 million. During the same quarter in the previous year, the company posted $0.64 earnings per share. The business’s revenue was up 19.5% on a year-over-year basis. On average, equities analysts expect that Incyte Co. will post 4.86 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Asset Management One Co. Ltd. boosted its position in Incyte by 0.4% during the fourth quarter. Asset Management One Co. Ltd. now owns 89,284 shares of the biopharmaceutical company’s stock valued at $6,181,000 after acquiring an additional 397 shares during the last quarter. Capital Performance Advisors LLP boosted its position in Incyte by 427.8% during the fourth quarter. Capital Performance Advisors LLP now owns 3,621 shares of the biopharmaceutical company’s stock valued at $250,000 after acquiring an additional 2,935 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its position in shares of Incyte by 2.3% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 61,975 shares of the biopharmaceutical company’s stock worth $4,281,000 after purchasing an additional 1,416 shares in the last quarter. Sanctuary Advisors LLC boosted its position in shares of Incyte by 29.8% during the 4th quarter. Sanctuary Advisors LLC now owns 27,330 shares of the biopharmaceutical company’s stock worth $2,016,000 after purchasing an additional 6,274 shares in the last quarter. Finally, CIBC Asset Management Inc boosted its position in shares of Incyte by 4.7% during the 4th quarter. CIBC Asset Management Inc now owns 26,493 shares of the biopharmaceutical company’s stock worth $1,830,000 after purchasing an additional 1,190 shares in the last quarter. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.